While a fatality has been reported following the administration of the COVID-19 Janssen vaccine, the South African Health Products and Regulatory Authority (SAHPRA) has emphasised that benefits of the vaccine greatly outweigh any adverse events that may occur following immunisation.<\/P>
The assertion follows the death of a patient, who was diagnosed with Guillain-Barre (GBS) Syndrome after receiving the COVID-19 Janssen vaccine. <\/P>
\u201cThe causality assessment was conducted by the National Immunisation Safety Expert Committee (NISEC) through a thorough methodology that is guided by the World Health Organization (WHO) and this is a methodology that is utilised by regulators across the world.<\/P>
\u201cIn this assessment, there is a conclusion that this case of GBS was associated with the event the individual had received the COVID-19 Janssen vaccine,\u201d SAHPRA CEO, Dr Tumi Semete-Makokotlela, said on Thursday.<\/P>
Addressing a media briefing on adverse events following immunisation, Semete-Makokotlela said SAHPRA authorised the COVID-19 Janssen last year in March for the administration of those who are 18 years and older.<\/P>
\u201cHaving looked at the ongoing review on vaccine safety, the review of the potential risk of GBS and this tragic case as well, we are convinced that the benefits of the COVID-19 vaccine in terms of preventing serious and severe COVID-19 infections and death, greatly outweigh the very rare GBS and other adverse events,\u201d said Professor Marc Blockman.<\/P>
Blockman is a Professor in the Internal Medicine department, and consultant in the division of Clinical Pharmacology at Groote Schuur Hospital and the University of Cape Town. He is recognised as an expert on International, National and Provincial Drug Policy and serves on SAHPRA as chairperson of the pharmacovigilance expert committee and member of the clinical expert committee.<\/P>
He said when the regulator looked at the vaccine programme, it was acutely aware of the inherent risk, and that GBS may be one of the adverse events the country might have to deal with.<\/P>
\u201cGBS is a rare entity that affects the immune system of patients. It affects about 100 000 people globally, which is a small group of patients that are affected in the world.<\/P>
\u201cIt is about 1 in 100 000 patients that may have GBS. It is characterised by this very rapid, progressive and ascending weakness, which means the weakness starts from the lower limbs and eventually ascends up the body.<\/P>
\u201cIt may cause limb weakness, it has the potential to affect the respiratory system, which may require the patient to be assisted with a ventilation and it may affect the brain as well,\u201d Blockman said.<\/P>
There are many causes of GBS, which include viruses and bacterial infections. The disease can be mild to very serious.<\/P>
Since the introduction of COVID-19 vaccines, commonly known as Pfizer and Johnson & Johnson, more than 37.2 million doses been administered.<\/P>
Up until the 15 July 2022, just over 6 200 adverse events have been reported to SAHPRA, which indicates a reporting of adverse events of just around 0.017%.<\/P>
Vaccines are safe, effective and prevent various infectious diseases<\/P>
Minister of Health, Dr Joe Phaahla, reiterated that immunisation remains one of the most successful and cost effective public health intervention.<\/P>
\u201cI want to emphasise that COVID-19 vaccines remain safe and effective in protecting us against serious illness and hospitilisation. Annually, over 27 million vaccine doses are administered as part of our routine immunisation programme and this is mainly for children.<\/P>
\u201cVaccines are safe and effective and prevent various infectious diseases, disability, hospitalisation and death caused by vaccine preventable diseases. However, as with various other medicines, including vaccines, adverse events do occur,\u201d Phaahla said.<\/P>
He described an adverse event following immunisation as any untoward medical event after immunisation, which does not necessarily and generally have a causal relationship with the use of the vaccine.<\/P>
\u201cThis may be an unfavourable or unintended sign, abnormal laboratory findings, symptoms or disease. Most adverse events following immunisation are mild and resolved within a few days,\u201d the Minister said.<\/P>
Adverse events following immunisations are reported through a well-established reporting system in corroboration with SAHPRA.<\/P>
Adverse events following immunisations can be reported through the Medicine Safety Application or the COVID-19 call centre or at any health facility in the country where trained health providers can identify, treat and report the adverse event.<\/P>
\u201cAfter an adverse event has been reported, all severe and serious adverse events are fully investigated by the provincial departments of health. This includes collecting all relevant medical reports such as the doctor\u2019s report, doctor\u2019s notes and laboratory result or hospital records.<\/P>
\u201cOnce the investigation is concluded the case [is] forwarded to NISEC. NISEC is a committee of experts appointed by the Minister of Health to review adverse events following immunisation reports,\u201d Phaahla said.<\/P>
<\/P>
<\/P>
<\/P>
Source: South African Government News Agency<\/P>
<\/P><\/p>\n","protected":false},"excerpt":{"rendered":"
While a fatality has been reported following the administration of the COVID-19 Janssen vaccine, the South African Health Products and Regulatory Authority (SAHPRA) has emphasised that benefits of the vaccine greatly outweigh any adverse events that ma…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[72],"tags":[],"yoast_head":"\n